evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

311 questions · 323 findings · 30 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 47 · 14.6%GRADE not reported 21 · 6.5%Very low 91 · 28.2%Low 65 · 20.1%Moderate 82 · 25.4%High 17 · 5.3%

Pericyazine vs atypical antipsychotics

Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia

It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Relapse · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Relapse compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
2 findings from 1 review

Levomepromazine vs Typical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review